Souhaitez-vous accéder aux communiqués récents ?

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....

LOS GATOS, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Radical™ Catheter Technologies, a NeuroTechnology Investors (NTI) portfolio company, today announced the U.S. Food and Drug Administration (FDA)...

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) --...

EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement,...

Austin, United States, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Brain Computer Interface Market Size & Growth Analysis: "According to SNS Insider, The Brain Computer Interface Market was valued at USD...

PathMaker Neurosystems Board Director, John Donoghue, Ph.D., Awarded 2026 Queen Elizabeth Prize for Engineering

Investigational ARC-BCI® Therapy is being developed to restore thought-driven movement in people living with spinal cord injuries and other movement disabilitiesARC-BCI is the world’s first and most...

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kaneka Medical America LLC, a subsidiary company of Kaneka Corporation, innovating embolization coil technology for neurovascular therapies, today...

PathMaker Neurosystems Announces Completion of ALS Early Feasibility Study of the MyoRegulator Device for Non-Invasive Treatment of ALS